- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe atopic dermatitis
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 431KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 81KB)
Dupilumab – July 2024
Dupilumab; Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent®
Last updated
30 May 2025